Comparative Pharmacology
Head-to-head clinical analysis: PROPOXYPHENE HYDROCHLORIDE W ASPIRIN AND CAFFEINE versus SOLARAZE.
Head-to-head clinical analysis: PROPOXYPHENE HYDROCHLORIDE W ASPIRIN AND CAFFEINE versus SOLARAZE.
PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE vs SOLARAZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a centrally acting opioid analgesic that binds to mu-opioid receptors. Aspirin inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. Caffeine is a CNS stimulant that may enhance analgesia.
Solaraze (diclofenac sodium) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation and pain. In actinic keratosis, it may also induce apoptosis and decrease keratinocyte proliferation.
1-2 capsules orally every 4-6 hours as needed; maximum 6 capsules per day. Each capsule contains propoxyphene hydrochloride 65 mg, aspirin 325 mg, and caffeine 32.4 mg.
Apply 0.5 mL (1 unit dose) topically to actinic keratoses twice daily for 2 to 4 weeks, then 1 week off, repeat for a total of 3 treatment cycles.
None Documented
None Documented
Propoxyphene: 6-12 hours (up to 36 hours in overdose); norpropoxyphene: 30-36 hours. Aspirin: 2-3 hours for low doses, up to 15-30 hours in overdose. Caffeine: 3-6 hours; prolonged in liver disease.
Following topical application, the terminal elimination half-life of diclofenac from plasma is approximately 12 hours (range 8-15 hours). This reflects the slow absorption and distribution from the skin depot, with clinical relevance for twice-daily dosing.
Renal elimination of propoxyphene and its metabolites (mainly norpropoxyphene) accounts for approximately 70-90% of the dose; fecal excretion is minimal (<10%). Aspirin is renally eliminated as salicylates (75-90% as conjugates, 10% free), while caffeine is primarily metabolized and its metabolites are excreted renally.
Solaraze (diclofenac sodium 3% gel) is primarily eliminated via hepatic metabolism followed by renal excretion of metabolites. Approximately 65% of a dose is excreted in urine as conjugated metabolites, with less than 1% as unchanged drug. About 35% is eliminated in feces via biliary excretion of metabolites.
Category D/X
Category C
NSAID / Antiplatelet
NSAID